Dr Kannan Vishwanatth A Charismatic Scientist Entrepreneur
Dr Kannan Vishwanatth A Charismatic Scientist Entrepreneur
Source: businessworld.in
Integrated Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Integrated Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Integrated Pharmaceutical Today - Breaking & Trending Today
Pharmaceutical Equipment Market Exhibits a Stunning Growth | Siemens, GE Healthcare, Bosch
Pharmaceutical Equipment Market Exhibits a Stunning Growth | Siemens, GE Healthcare, Bosch
Source: sandiegosun.com
Dr Reddys Lab Q4 PAT skids 28% to Rs 554 cr
On a consolidated basis, Dr Reddy's Laboratories' net profit dropped 28% to Rs 553.50 crore on 7% increase in revenues to Rs 4,728.40 crore in Q4 March 2021 over Q4 March 2020. Profit before tax jumped 13% to Rs 807.10 crore in Q4 FY21 as against Rs 714.20 crore in Q4 FY20. EBITDA rose 13.15% to Rs 1,133 crore in Q4 FY21 over Q4 FY20. EBITDA margin stood 24% in Q4 FY21 higher than 22.6% in Q4 FY20. Revenue in the Global Generics (CG) segment rose 6% to 3873.70 crore in Q4 FY21 over Q4 FY20. The YoY growth was driven by branded markets (India and emerging markets), while Europe was partly off...
Source: business-standard.com
Dr Reddy's Lab launches Fluphenazine Tablets in US
Dr Reddy's Laboratories along with its subsidiaries announced the launch of Fluphenazine Hydrochloride Tablets, USP, in the U.S. market. The company along with its subsidiaries today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA). The Prolixin brand and generic had U.S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020 according to IQVIA Health. Dr Reddy's Fluphenazine Hydrochlo...
Source: business-standard.com
Dr. Reddy's Labs rises on launching febuxostat tablets in US
Dr. Reddy's Laboratories gained 1.3% to Rs 5406.70 after the drug major announced the launch of febuxostat tablets in the US market.Febuxostat tablets are a therapeutic equivalent generic version of Uloric (febuxostat) tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had US sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health. Dr. Reddy's febuxostat tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets. Dr. Reddy's Laboratories is an integrated...
Source: business-standard.com